Ftse Mib
34.720,35
0,90%
DAX
19.473,63
1,32%
S&P 500
5.738,17
-0,13%
NASDAQ
18.119,59
-0,39%
Bitcoin
65.802,85
0,95%
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ BioCardia Inc (BCDA) BioCardia Inc (BCDA) Notizie

BCDA

BioCardia (BCDA)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:BCDA
DataOraFonteTitoloSimboloCompagnia
18/09/202414:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BCDABioCardia Inc
18/09/202414:30GlobeNewswire Inc.BioCardia Regains Full Compliance with Nasdaq Listing RequirementsNASDAQ:BCDABioCardia Inc
09/09/202422:05GlobeNewswire Inc.BioCardia Announces Closing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq RulesNASDAQ:BCDABioCardia Inc
07/09/202401:45Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:BCDABioCardia Inc
05/09/202418:42Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BCDABioCardia Inc
30/08/202423:21Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:BCDABioCardia Inc
30/08/202414:00GlobeNewswire Inc.BioCardia Announces Pricing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq RulesNASDAQ:BCDABioCardia Inc
30/08/202406:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:BCDABioCardia Inc
30/08/202402:09Edgar (US Regulatory)Form S-1MEF - Registration adding securities to prior Form S-1 registration [Rule 462(b)]NASDAQ:BCDABioCardia Inc
29/08/202414:30GlobeNewswire Inc.BioCardia Announces FDA Market Clearance of Morph® DNA™ Steerable Introducer Product FamilyNASDAQ:BCDABioCardia Inc
29/08/202412:02Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:BCDABioCardia Inc
21/08/202413:00GlobeNewswire Inc.FDA Approves CardiAMP® Heart Failure II Protocol Amendment to Use Proprietary Cell Population Analysis Screening to Define TreatmentNASDAQ:BCDABioCardia Inc
13/08/202422:30GlobeNewswire Inc.BioCardia Reports Second Quarter 2024 Business Highlights and Financial ResultsNASDAQ:BCDABioCardia Inc
13/08/202419:57Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:BCDABioCardia Inc
09/08/202422:40Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:BCDABioCardia Inc
07/08/202413:00GlobeNewswire Inc.BioCardia to Host Q2 2024 Corporate Update and Financial Results Conference Call on August 13, 2024NASDAQ:BCDABioCardia Inc
02/08/202423:01Edgar (US Regulatory)Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securitiesNASDAQ:BCDABioCardia Inc
30/07/202413:00GlobeNewswire Inc.BioCardia Submits for FDA Approval of Morph® DNA™ Steerable Introducer Product FamilyNASDAQ:BCDABioCardia Inc
25/07/202413:00GlobeNewswire Inc.Patient Enrollment Commenced in Pivotal Phase 3 Trial of CardiAMP Cell Therapy for the Treatment of Ischemic Heart FailureNASDAQ:BCDABioCardia Inc
17/07/202413:00GlobeNewswire Inc.BioCardia Announces United States Patent Issuance on Morph DNA Multi-Directional Steerable Catheter Transseptal ApplicationNASDAQ:BCDABioCardia Inc
08/07/202413:00GlobeNewswire Inc.CellProthera and BioCardia Collaborate on Successful Phase II Trial of ProtheraCytes™ for the Treatment of Acute Myocardial InfarctionNASDAQ:BCDABioCardia Inc
07/06/202413:00GlobeNewswire Inc.BioCardia Announces United States Patent Issuance on Intramyocardial Delivery of Cell Aggregates to the Heart Including Minimally Invasive Radial Artery ApproachNASDAQ:BCDABioCardia Inc
21/05/202423:00GlobeNewswire Inc.BioCardia Announces Reverse Stock SplitNASDAQ:BCDABioCardia Inc
14/05/202422:02GlobeNewswire Inc.BioCardia Reports First Quarter 2024 Business Highlights and Financial ResultsNASDAQ:BCDABioCardia Inc
01/05/202413:00GlobeNewswire Inc.BioCardia’s CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important OutcomesNASDAQ:BCDABioCardia Inc
25/04/202415:00GlobeNewswire Inc.BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In CohortNASDAQ:BCDABioCardia Inc
27/03/202421:00GlobeNewswire Inc.BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial ResultsNASDAQ:BCDABioCardia Inc
20/03/202412:00GlobeNewswire Inc.BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024NASDAQ:BCDABioCardia Inc
13/03/202412:00GlobeNewswire Inc.BioCardia and StemCardia Announce Biotherapeutic Delivery PartnershipNASDAQ:BCDABioCardia Inc
12/03/202412:00GlobeNewswire Inc.BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure StudyNASDAQ:BCDABioCardia Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:BCDA

La tua Cronologia

AMEX
SCYB
Schwab High Yield Bond ETF
BIT
3EUS
WisdomTree EURO STOXX 50...
USOTC
SOHVY
Sumitomo Heavy Industries (PK)
NASDAQ
MSS
Maison Solutions
HITB
FIDABTC
Bonfida
AQSE
SRE.GB
Sirius Re
TSX
GDEP
Guardian Directed Equity...
LSE
ALV
BOV
L1EG34M
Leggett Platt
USOTC
YAHOY
LY (PK)
AMEX
FHYS
Federated Hermes Short D...
ASX
DXSKOP
LSE
79UP
First.abu 26
USOTC
AJINF
Ajinomoto (PK)
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network